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a  b  s  t  r  a  c  t
Estimates  of the  marginal  effect  of  measures  of  adiposity  such  as body  mass  index  (BMI)
on  healthcare  costs  are important  for  the  formulation  and  evaluation  of  policies  targeting
adverse  weight  profiles.  Most  estimates  of  this  association  are  affected  by endogeneity
bias.  We  use  a novel  identification  strategy  exploiting  Mendelian  Randomization  –  random
germline  genetic  variation  modelled  using  instrumental  variables  – to  identify  the  causal
effect  of BMI  on  inpatient  hospital  costs.  Using  data  on over  300,000  individuals,  the effect
size  per  person  per  marginal  unit  of  BMI  per  year  varied  according  to  specification,  including
£21.22  (95%  confidence  interval  (CI):  £14.35-£28.07)  for conventional  inverse  variance





Effect  sizes  from  Mendelian  Randomization  models  were  larger  in most  cases  than  non-
instrumental  variable  multivariable  adjusted  estimates  (£13.47,  95% CI:  £12.51-£14.43).
There  was little  evidence  of non-linearity.  Within-family  estimates,  intended  to  address
dynastic  biases,  were  imprecise.
© 2020  The  Authors.  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the CC
BY  license  (http://creativecommons.org/licenses/by/4.0/).endelian Randomization
. Introduction
A positive association between adiposity and health-
are costs is well established. It has been documented for a
ariety of different contexts, circumstances and health sys-
ems (Cawley, 2015; Finkelstein and Yang, 2011; Withrow
nd Alter, 2011). This association has powerful economic
alience because of its apparent consequences for the level,
rowth and composition of healthcare spending.
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.0/).The underlying biological relationship between adipos-
ity and health is complex (Corbin and Timpson, 2016),
but the endocrinal (Corbin et al., 2016), cardiometabolic
(Emdin et al., 2017; Lyall et al., 2017) and other changes
(Wang et al., 2011) associated with increased adiposity
are themselves linked to substantial healthcare resource
requirements (Lehnert et al., 2013). These demands on
healthcare resources have arisen in a wider context in
which increases in the mean and variance of adiposity,
reflected in widely used measures of nutritional sta-
tus such as body mass index (BMI - weight divided by
the square of standing height) have led to important
changes in the global distribution of adiposity (Davey
Smith, 2016; Finucane et al., 2011; N. C. D. Risk Factor
Collaboration, 2016). The worldwide prevalence of over-
weight (BMI> = 25 kg/m2) and obesity (BMI> = 30 kg/m2) is
article under the CC BY license (http://creativecommons.org/licenses/by/
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28.8% for men  and 29.8% for women. This accounts for
some 2.1 billion individuals, an increase of approximately
50% since 1980 (Ng et al., 2014). More individuals globally
are now either overweight or obese than are underweight
(Black et al., 2013; N. C. D. Risk Factor Collaboration, 2016).
Correlational evidence of the BMI-cost association is
influential. Examples of this influence include the devel-
opment of guidelines and policies to prevent obesity
(Government Office for Science, 2007), evaluation of inter-
ventions targeting overweight and obesity (Avenell et al.,
2004), and the prioritization of research into the con-
sequences of obesity (Kraak et al., 2005). However, a
critical limitation of much if not all of this multivariable
or conditional correlational1 research is that it can be seri-
ously affected by endogeneity bias (Auld and Grootendorst,
2011).
This endogeneity arises through three channels. The
first is measurement error arising from mismeasurement of
BMI  (and other measures of adiposity), particularly where
individuals self-report weight (Burkhauser and Cawley,
2008; Cawley et al., 2015a). The second is reverse causa-
tion or simultaneity bias, which would occur if healthcare
costs influenced adiposity. The third source of bias is omit-
ted variable bias, arising from unknown or unmeasured
common causes of both adiposity and healthcare costs.
The direction of the omitted variable bias will generally
not be known a priori. Disease processes that are related
to healthcare costs may  also influence adiposity. For exam-
ple, higher BMI  is associated with increased risk for cancers
(Lauby-Secretan et al., 2016), but cancer (including prodro-
mal  cancer) may  itself lead to reductions in BMI  (Tisdale,
2002). Similarly, people with higher BMI  are more likely to
smoke, while smoking itself lowers BMI  (Carreras-Torres
et al., 2018; Taylor et al., 2018). Without evidence of the
wider determinants of both adiposity and healthcare cost,
the analyst cannot reliably predict directions of bias when
undertaking multivariable analyses of this association.
BMI-health outcome associations are therefore dis-
torted because one of the drivers of healthcare costs is own
health status. Reliable evidence of the causal association
between adiposity and healthcare costs is a critical input
for the formulation and evaluation of cost-effective poli-
cies and interventions targeting (in particular) overweight
and obesity (Wang et al., 2011), as well as for identifying
research priorities in this area. The widespread use of mod-
els lacking robust identification may  substantially under-
or over-estimate the true causal effects of BMI.
This observation has motivated attempts to use instru-
mental variable (IV) analyses in which the instrument for
own BMI  is the BMI  of a biological relative, for example
in relation to the association between BMI  and mortality
(Davey Smith et al., 2009). This approach has also been
1 Henceforth we use “multivariable” or “multivariable conditional cor-
relation” as shorthand for all study designs and estimators that do not use
either formal randomization or reliance on some kind of natural experi-
ment. We avoid the use of the term “observational” for this purpose, as
Mendelian Randomization is itself a form of observational analysis. We
also avoid the use of ordinary least squares (OLS) as shorthand for these
other study designs as the estimators used were not necessarily of this
type.al of Health Economics 70 (2020) 102300
used to model the causal impact of adiposity on costs, and
arguably represents the most credible attempt to date to
overcome the endogeneity biases of conventional multi-
variable analysis.
For example, Cawley and Meyerhoefer (Cawley and
Meyerhoefer, 2012) used the BMI  of a biological relative
as an IV. This suggested that the healthcare costs of obe-
sity were drastically underestimated by prior multivariable
conditional correlational analyses, with a fourfold differ-
ence in the marginal costs of obesity between multivariable
and causal IV analysis reported, and a threefold difference
in the costs of a marginal unit of BMI. Large but less pro-
nounced differences between multivariable and IV models
were also reported in studies using similar instruments by
Black et al. (2018b), Cawley et al. (2015b), Doherty et al.
(2017) and Kinge and Morris (2018).
However, this approach does have limitations. The asso-
ciation of biological relatives and healthcare costs may
itself be affected by omitted variables that are common
and independent causes of both BMI  and healthcare costs.
These could include the home environment that is shared
by biological relatives and which may  influence food con-
sumption, proclivity to exercise, and access to and use of
healthcare services. People who have children (necessary
for the biological relative approach) may  differ from those
who  do not have children. Intrauterine influences of mater-
nal BMI  on offspring BMI, such as smoking and alcohol
drinking during pregnancy (Lawlor et al., 2017), and genetic
influences that affect healthcare costs other than through
adiposity (Dixon et al., 2016), will also confound this rela-
tionship.
This paper exploits a novel identifying approach -
germline genetic variation associated with BMI – in an
instrumental variable analysis. This approach has the
advantage (in principle) of avoiding the limitations of both
multivariable conditional correlational analysis and the use
of a biological relative as an instrument.
At each point of variation in the genome, offspring
inherit one allele from their mother, and one from their
father. An allele is the specific adenine (A), cytosine (C), gua-
nine (G) or thymine (T) nucleobase that is inherited at each
point of variation in the genome. This inheritance of alleles
is a natural experiment, in which individuals in a popula-
tion can be divided into groups based on their inherited
“dose” of these variants (Evans and Davey Smith, 2015). If
the instrumental variable assumptions hold, these genetic
variants can be used to test whether BMI  affects healthcare
costs.
Using genetic variants as IVs in this way  has become
known as Mendelian Randomization (Davey Smith and
Ebrahim, 2003). Very large, high-quality datasets that can
facilitate this type of analysis are beginning to become
available (Collins, 2012; Sudlow et al., 2015) but remain
largely if not entirely unexploited by health economists
studying the causal effect of health conditions and traits
on cost outcomes. Our results indicate that our base point
effect estimates (obtained from inverse variance weighted
Mendelian Randomization models) for a marginal unit of
BMI  £21.22 (95% confidence interval (CI): £14.35-£28.07)
are approximately 57% larger than non-instrumental vari-






















































allele frequencies, is another means by which the second
assumption may  be violated, since differences in alleles inP. Dixon, W.  Hollingworth, S. Harrison et a
12.51-£14.43). The Mendelian Randomization effect esti-
ates attenuate somewhat under sensitivity analyses that
re robust to violations of the exclusion restriction. For
xample, estimates from the penalized weighted median
odel (£18.85 (95% CI: £9.05-£28.65)) are lower than the
nverse variance weighted estimate but still higher than the
onventional non-instrumental variable point effect.
Below, we set out the broad context of our analysis by
rst reviewing how the biology of genetic variation and
onditionally random allocation of genetic variation at con-
eption might be used as instrumental variables in general.
e relate how the general principles of Mendelian Ran-
omization operate in the specific empirical context of
ur research question. We  then present our approach to
stimation and sensitivity analysis, in which we test, as
igorously as possible, assumptions that are both general
o instrumental variable analysis and those that are spe-
ific to Mendelian Randomization. This latter analysis has
 particular focus on assessing the impact of heterogeneity
t the level of genetic variants.
These methods are applied to data from the UK Biobank,
n exceptionally large, detailed and high-quality geno-
yped dataset that is linked to the universe of publicly
unded inpatient hospital care episodes. We  interpret our
esults in relation to their policy implications, having
egard to the limitations of this analysis.
. Methods
.1. Mendelian Randomization and instrumental
ariable analysis
Here, we briefly introduce the high-level biological
echanisms that motivate the use of genetic variants
n IV analysis. More detailed introductions and extended
verviews of Mendelian Randomization are available else-
here (Davey Smith and Hemani, 2014; Davies et al., 2018;
ingault et al., 2018; von Hinke et al., 2016).
A single nucleotide polymorphism (SNP) is a specific
ocation (or locus) in the human genome that differs
etween people in the population. At each SNP people
ill have two  alleles, one for each chromosome. Dur-
ng cell division at conception (meiosis), offspring inherit
t random one of their mother’s two alleles, and one of
heir father’s two alleles. Specific SNPs or sets of SNPs are
nown to associate with particular health conditions or to
nfluence the development of particular traits. Thus, the
henotype (a measurable disease or trait such as BMI) may
e influenced by genotype (an underlying genetic structure
ssociated with the phenotype).
The provenance of the term Mendelian Randomization
Davey Smith, 2007), and the potential utility of genetic
ariants as IVs, is founded on Mendel’s first and second
aws of inheritance. The first law describes random segre-
ation of alleles from parent to child during the formation
f gametes. The second law describes the independent
ssortment of alleles for different phenotypes at concep-
ion. Genetic variants that are in different locations in
he genome are generally inherited in a way that is inde-
endent of the inheritance of other genetic variants. Theal of Health Economics 70 (2020) 102300 3
allocation of these genetic variants to offspring is therefore
random, conditional on parental genotype.
We  now describe the core instrumental variable
assumptions in the context of Mendelian Randomization.
These assumptions can be described as comprising the rel-
evance assumption, the independence assumption, and the
exclusion restriction. In what follows we  refer interchange-
ably to SNPs, variants and genetic variants.
The first IV assumption (“relevance”) is that the instru-
ment should be associated with the treatment variable,
which in this paper is BMI.2 Some of the initial IV stud-
ies using genetic variation in economics (e.g. (Ding et al.,
2009; Fletcher and Lehrer, 2011; Norton and Han, 2008))
relied on evidence of relevance obtained from so-called
“candidate gene” studies, which proceed from an assumed,
anticipated or measured relationship between particular
regions of the genome and a phenotype of interest. Rel-
evance can be threatened in these circumstances, since
these associations were often not robustly tested and can-
didate gene associations have been observed to have poor
replicability (Benjamin et al., 2011, 2012; Chabris et al.,
2015; Ioannidis et al., 2011). As could have been anticipated
(Colhoun et al., 2003), Fletcher (Fletcher, 2018) notes of this
early economics literature that “Indeed, in hindsight, one
might expect that none of the results reported in papers
using candidate gene approaches are robust.”
We  anticipate that the relevance assumption will be
readily met in our study since we do not use a candidate
gene approach. The associations of SNPs with diseases and
traits are in general better determined from genome wide
association studies (Hirschhorn and Daly, 2005; McCarthy
et al., 2008), which study the independent association
with specific phenotypes of many SNPs - potentially mil-
lions - across the genome. These associations are corrected
for multiple testing so that genome-wide significance is
obtained as the conventional p-value threshold value based
on an alpha of 0.05 divided by k, where k can be inter-
preted (conservatively) as the number of independent
statistical tests conducted across the genome (Bush and
Moore, 2012). These associations will be validated in inde-
pendent replication samples. Following convention, we
will describe p< = 5 × 10−8 as genome-wide significant. We
describe the genome wide association studies that we use
in the Data section.
The second assumption is that there are no omitted
variables in the associations of the IV and the outcome
(healthcare costs). This assumption is plausible since SNPs
are determined at conception, and therefore prior to
the postnatal circumstances, events and behaviours of
later life. However, time of conception (such as month
or year of birth) could theoretically associate with SNPs
and healthcare costs. Population stratification, the sepa-
ration of individuals into distinct subgroups that differ in2 The treatment variable is sometimes referred to as the exposure, the
modifiable factor, the risk factor or the intermediate phenotype. Following
the econometrics literature, we will refer to BMI  as the treatment variable.
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this case would indicate differential ancestry rather than
disease susceptibility (Cardon and Palmer, 2003).
Ancestry influences the distribution of genetic variants,
but also risks of disease not necessarily attributable to those
variants. This potential confounding by ancestry is typically
accounted for by adjusting for the genetic principal com-
ponents and restricting analysis to genetically homogenous
ethnic groups. Fletcher (Fletcher, 2018) further notes that
failure to control for population structure is also likely to
have affected early economic studies using Mendelian Ran-
domization.
This can introduce bias induced by spurious associa-
tions. A notable example of this is provided by Rietveld
et al. (Rietveld et al., 2014) as follows. Genome wide
association studies of educational attainment would find
associations between education and a gene for lactase
persistence, because both educational attainment and
lactase persistence vary by ancestry. However, lactase
persistence is almost certainly unrelated to cognitive influ-
ences on educational attainment. This spurious association
remained after restricting analysis samples according to
self-reported ethnicity, but was removed when adjust-
ments were made for genetic principal components.
Simultaneity bias, if present at all and absent population
stratification, is likely to be modest in the case of adipos-
ity and healthcare costs. Examples of the independence of
common genetic variation from common omitted variables
(and thus that SNPs are likely to be independent of envi-
ronmental influences in support of this assumption) has
been demonstrated empirically (Davey Smith and Hemani,
2014; Davey Smith et al., 2007).
The third IV assumption is that the SNP(s) affect the
outcome only via the treatment variable; that is, via the
condition or trait of interest. This is the exclusion restric-
tion. Violations of this assumption are the primary threat to
the validity of IVs used in Mendelian Randomization. There
are two principal mechanisms by which this assumption
may  be violated in Mendelian Randomization.
The first is the correlation of the SNP(s) in question
with other SNPs that affect the outcome through a path
other than via the condition or trait of interest (Lawlor
et al., 2008). This correlation of variants, known as linkage
disequilibrium, arises when particular variants tend to be
inherited together (contrary to Mendel’s second law), gen-
erally because they are located in close physical proximity
on the genome (Visscher et al., 2012).
The second mechanism concerns variants that affect
more than one phenotype through independent path-
ways (Cawley et al., 2011; Davey Smith and Hemani,
2014; Hemani et al., 2018a). A SNP that affects BMI  may
also, for example, affect the risk of depression through
a BMI–independent mechanism. IV analysis relating, for
example, a set of BMI  SNPs to healthcare cost outcomes
would suffer from bias in this case if depression inde-
pendently affects both BMI  and healthcare costs. This is
sometimes known as horizontal pleiotropy (Davey Smith
and Hemani, 2014). Pleiotropy (Paaby and Rockman, 2013;
Stearns, 2010) is the effect of a single SNP on multiple phe-
notypes (Lobo, 2008; Stearns, 2010). There would be no bias
in this analysis if depression was on the causal pathway
between BMI  and healthcare costs, a situation sometimesal of Health Economics 70 (2020) 102300
referred to as vertical pleiotropy (Davey Smith and Hemani,
2014), or if the other phenotype did not affect the outcome
of interest.
Our starting position is that horizontal pleiotropy, in
violation of the exclusion restriction, is likely to be present
amongst some of the SNPs that we study. This is both
because pleiotropy appears to be pervasive throughout the
human genome (Hemani et al., 2017), and because of the
outcome that we study. Our outcome, hospital costs, can
be influenced by anything that is associated with hospital
attendance. This may  open horizontal pleiotropic pathways
that may  not be observed when studying other economic
outcomes.
For example, both excess adiposity and depression may
influence hospitalization, whereas either of these pheno-
types may  or may  not influence performance on a different
outcome such as an academic test of intelligence. Our
response to the possibility of pleiotropy is to test for its
presence, and to implement pleiotropy-robust estimators
as described below. Our work represents an early appli-
cation of many of these methods in the health economics
literature.
We now consider monotonicity. Monotonicity requires
that the direction of effect on the treatment from vary-
ing the level of the instrumental variable should be in the
same direction for all individuals. When monotonicity is
satisfied, IV analysis (including Mendelian Randomization)
identifies a local average treatment effect; that is, an effect
in those whose treatment would differ if the value of the
IV differed. This is the average effect of BMI  on hospital
costs for individuals whose BMI  was  affected by the 79 BMI
increasing SNPs. Mendelian Randomization therefore does
not identify population average treatment effects.
The consequence of the monotonicity assumption is
that for all individuals at all 79 SNPs, replacing an allele
associated with lower BMI  with an allele increasing BMI
would either increase BMI  or leave their BMI  unchanged.
Monotonicity may  be biologically plausible (Burgess and
Thompson, 2015a) but cannot be demonstrated empiri-
cally, since to do so would require a comparison of the
consequence for BMI  of replacing an individual’s observed
BMI  associated genotypes with a counterfactual alternative
genotype.
In conventional instrumental variable models, com-
pliers (individuals who satisfy these assumptions) are a
subgroup of our entire analysis sample but generally can-
not be identified. This subgroup may  be equivalent to the
entire analysis sample, or may  constitute a large or small
subgroup of that sample. Note that because BMI  is con-
tinuous variable, it is reasonable to consider the LATEs as
reflecting the impact of the SNPs across the entire distribu-
tion of BMI. This would suggest that the complier subgroup
could comprise the entirety of our sample. Thus, it is plau-
sible that the average treatment effect is equivalent to the
LATE since the effects of BMI  on compliers are likely to be
similar to the effects of BMI  on average across the wider
population.In any event, there is no evidence from the Locke et al.
GWAS (Locke et al., 2015) on which we  rely that BMI-SNP
associations have the opposite sign (violating monotonic-
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onduct our analysis and report its findings under the
ssumption that monotonicity holds for most if not all of
ur analysis sample. I.e. that the local average treatment
ffect identified by our estimator is equal to the average
ffect in the population.
Finally, that all of the preceding assumptions may  be
et  in a particular example does not guarantee that reliable
ausal inferences can be obtained if the instrumental vari-
bles are weak. Weak instruments are another of the issues
dentified by Fletcher (Fletcher, 2018) as affecting earlier
conomic literature, despite recognition in initial eco-
omics discussions of Mendelian Randomization (Fletcher,
011; von Hinke Kessler Scholder et al., 2011) and in more
ecent analyses (Davies et al., 2015; von Hinke et al., 2016)
f the importance of strong instruments. Even if SNPs sat-
sfy the relevance assumption at genome-wide levels of
ignificance, it is possible that they are “weak” instru-
ents, in the sense of explaining only a small proportion
f the variance in the treatment in any given finite sample
Burgess et al., 2015; Davies et al., 2015). Weak instruments
ill bias the causal estimate in finite samples toward the
on-IV estimate in one sample models and toward the null
n two-sample Mendelian Randomization models (Burgess
nd Thompson, 2015a; Davies et al., 2015) and will affect
he estimate precision in all cases (von Hinke et al., 2013).
Our approach to instrument strength is a point of depar-
ure from the earlier Mendelian Randomization economics
iterature. We  report the proportion of variance explained
n BMI  by our instruments, compare our base case esti-
ates to a method robust (under assumptions) to weak
nstruments, and we use some of the largest samples
tudied to answer this research question. We  estimate
ur base models on over 300,000 unrelated individuals in
opulation-wide analysis, and over 28,000 related individ-
als for our within-family analysis.
.2. Model estimation
For a single SNP, the ratio (or Wald) estimator can be
alculated as the ratio of the SNP-outcome to the SNP-
reatment variable (BMI) associations. This gives the effect
f the variant on the outcome, scaled by the effect to the
NPs on the treatment. This is equivalent to the two-stage
east squares estimator for a single SNP. Using the termi-
ology of Bowden et al. (2015), indexing individuals by i
nd denoting SNPs as G (indexed j from 1 up to J) these two








˛jGij + ˇXi + εYi (2)
Without loss of generality, we ignore constants and
xogenous omitted variables in Eqs. (1) and (2). The alpha
erm is the direct effect of variants on the outcome that
o not operate through the BMI  treatment variable. If
he exclusion restriction holds then alpha will be zero,al of Health Economics 70 (2020) 102300 5
since valid instruments influence outcomes only through
an effect on the treatment.
Note also that the two associations described in Eqs. (1)
and (2) in the Wald estimator need not come from the same
sample, in which case a two-sample IV estimator is used
(Angrist and Krueger, 1992). A two-sample approach using
summarized data may  offer similar or better efficiency than
a single sample study using individual-level data, particu-
larly if larger sample sizes are available under a two-sample
approach. In the two-sample setting, genetic variants must
have similar effects in each population (Haycock et al.,
2016).
Rewriting Eqs. (1) and (2) into the reduced form, and
using ε‘Y
i
to denote the error term, yields:
Y = jGij + ε‘Yi = (˛j + ˇj)Gij + ε‘Yi (3)
The ratio estimate is ratio of the effect of the SNPs on
the outcome (j), scaled by their effect on the treatment
(j), which can be written (ignoring the error term) as:
j
j




+  ̌ (4)
The ratio estimates from each individual variant can
be combined using weighted regression or equivalently
inverse variance weighted (IVW) meta-analysis to produce
an overall causal estimate (henceforth for simplicity we
refer to this estimate as the IVW estimate – Eq. (5)). This
assumes that there no correlation between the Wald esti-

















Here, the −2Yj terms are the variance of the error term in
the outcome-SNP regression models; the small variance of
the error term in the treatment-SNP regression is ignored
(the no-measurement error assumption).
If the exclusion restriction holds, there should be no
more heterogeneity in the estimates for all SNP effect sizes
than would be expected by chance. This can be assessed
using Cochran’s Q statistic (Cochran, 1950; Higgins and
Thompson, 2002) in two-sample settings (this is closely
related to Sargan’s over-identification test (Sargan, 1958)),







( ˆ̌ j − ˆ̌ IVW ) (6)
Cochran’s Q can identify failure of the instrumental vari-
able assumptions, but not whether this is due to one, some
or all IVs being invalid, or why  they are invalid. As such, it
is a relatively crude “catch all” test of instrument validity.
Nevertheless, it is useful as a first step to indicate the pres-
ence of heterogeneous causal effects across the instrument
l. / Journ6 P. Dixon, W.  Hollingworth, S. Harrison et a
set, which may  be due to pleiotropy, but potentially also
other violations of the instrumental variable assumptions.
2.3. Sensitivity analysis
A number of methods have been developed to accom-
modate violations of the exclusion restriction due to
pleiotropy that is suggested by (but not necessarily unam-
biguously identified by) high heterogeneity as determined
by Cochran’s Q (Davey Smith et al., 2018; Hemani et al.,
2018a). The following considers some of these methods,
which follow the spirit of Conley et al. (2010) in relaxing
the assumption that the ˛j parameter of Eq. (4) is exactly
zero. The underlying goal is to apply methods to generate
consistent estimates of the causal effect even if some or all
of the IVs are invalid.
If pleiotropy (i.e. non-zero ˛j terms) is present but small
in magnitude, then biases in any causal analysis will be
modest. If ˛j is zero on average across all SNPs then the
relationship is estimated with more noise and hence some
loss of efficiency than if all ˛j values were zero, but the
bias term will have zero mean on average even if some or
all of the pleiotropic effects are large. In this case, the IVW
estimator could be implemented using a random effects
meta-analysis.
If the mean effect of alpha is not zero, then directional
pleiotropy is present. So-called MR-Egger methods allow
for directional pleiotropy by modelling both the slope and
intercept of the ratio estimator of Eq. (4).
̂j = ˇ0 + ̂jˇ1 + εYi (7)
Note that the “̂ , ̂j” terms included in Eq. (7) are them-
selves estimates, respectively of the SNP-cost and SNP-BMI
estimates. MR-Egger estimators are less powerful and less
efficient than the estimators discussed below because of
the need to estimate both the slope parameter and the
intercept parameter.
All SNPs can be invalid instruments under MR-
Egger, provided that the InSIDE (Instrument Strength
Independent of Direct Effect) assumption holds. The MR-







can be re-expressed as the true effect estimate ˆ̌  plus a
bias term
cov( ˆ̨ , ̂j)
var( ̂j)
. The bias term will be zero when the
numerator is zero – that is, when instrument strength ( ̂j)
is independent of the direct effect ( ˆ̨ ) of the SNPs on the
outcome.
This is the InSIDE assumption, and appears to be plau-
sible in some cases (e.g. (Pickrell et al., 2016)) but not
in others (e.g. (Bowden et al., 2015; Davey Smith and
Hemani, 2014)). The assumption will hold in circumstances
where genetic associations with other variables are uncor-
related with each other (Pickrell et al., 2016) (Burgess and
Thompson, 2017). It may  also hold when pleiotropy is hor-
izontal, which would rule out a direct effect of a variant
contributing to instrument strength.
The InSIDE assumption can be violated if, following
(Burgess and Thompson, 2017), SNPs influence omitted
variables in the BMI-outcome association. For example,al of Health Economics 70 (2020) 102300
consider SNPS that have horizontal pleiotropic effects on
some health condition that is such an omitted variable.
In this case, there will be a positive correlation between
these pleiotropic effects and instrument strength, since
instrument strength will be inflated by the influence of the
pleiotropic variants. This will induce covariance between
strength and the direct effect of pleiotropic variants, in
violation of the InSIDE assumption. In general, SNPs with
larger effects on these omitted variables will tend to have
larger pleiotropic effects and higher instrument strengths.
Burgess and Thompson (Burgess and Thompson, 2017)
conclude “It is difficult to imagine how the InSIDE assump-
tion could be satisfied if several genetic variants have
pleiotropic effects acting via confounders.”
An alternative to relying on the InSIDE assumption is to
use the median ratio estimate of all available instruments
(Bowden et al., 2016). This estimator will be unbiased if
more than half of the instruments are valid, i.e. ˛j = 0 for
at least half of all SNPs. The simple intuition for this esti-
mator is that invalid instruments in the IVW approach
will contribute weight to the overall regression estimate
and will be biased even asymptotically. On the assump-
tion that the majority of instruments are valid, then invalid
instruments contribute no weight and are less biased than
IVW in finite samples and unbiased asymptotically. We
implement a penalized weighted median estimator. SNPs
contributing to the median 50% of the statistical weight are
used to form the median estimate. The weights are a func-
tion of the precision with which SNPs are estimated in the
Locke et al. (2015) genome wide association study, and the
penalization involves “down weighting” outlying SNPs that
contribute substantial heterogeneity to the Q statistic.
The final class of estimators we  consider are mode based
(Hartwig et al., 2017). The underlying assumption, in terms
of the alpha expression, is that Mode (˛1, ˛2, . . .˛k) = 0.
The intuition is that classifying variants into clusters based
on similarity of effect will be consistent if the largest
homogenous cluster are valid SNPs. All other SNPs outside
this cluster, even a majority of SNPs, could be invalid, pro-
vided this “zero modal pleiotropy” assumption holds. This
approach requires the setting of an arbitrary bandwidth
parameter to define the clusters. We implement a more
efficient version of the simple mode estimator by weight-
ing median estimates by the inverse variance of the effect
of the SNPs on the outcome. This is given effect by creating
an empirical density function formed from the weighted
mode estimates.
It is important to note that the second and third IV
assumptions are not directly testable, and the assumptions
underlying alternative modelling approaches for ˛j term
are themselves untestable. However, these approaches
are important forms of sensitivity analysis that allow the
instrumental variable assumptions to be relaxed, albeit
at the cost of other untestable assumptions. Similarity of
estimated effect under each of the estimators considered
would offer some reassurance that the same causal effect
is being identified, although it is important to note that
MR-Egger is much less precise than other estimators.
It is also important to note the Mendelian Randomiza-
tion is most robust within the family unit, since genetic
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ndependent, random meiotic events. This point was
ade in the first extended systematic formulation of the
otion, in 2003 (Davey Smith and Ebrahim, 2003): “The
asis of Mendelian randomization is most clearly seen in
arent–offspring designs that study the way phenotype
nd alleles co-segregate during transmission from par-
nts to offspring. . ..  Thus the Mendelian randomization
n genetic association studies is approximate, rather than
bsolute”. It was also made as far back as RA Fisher’s artic-
lation (Fisher, 2010) of the logic of statistical genetics
n 1951: “The different genotypes possible from the same
ating have been beautifully randomised by the meiotic
rocess. A more perfect control of conditions is scarcely
ossible, than that of different genotypes appearing in the
ame litter.”
The central issue then becomes whether the approxima-
ion is “good enough” for the purposes of making reliable
nferences under population-wide MR.  On the one hand,
he independence of allele scores from large numbers
f non-genetic potential confounding variables has been
emonstrated (e.g. (Davey Smith et al., 2007; von Hinke
essler Scholder et al., 2014)), which suggests that ran-
om allocation of alleles at the level of the parent-child
elationship during conception holds, conditional on pop-
lation structure, outside of the family trio. Using a single
ndividual from each family should not suffer from omitted
ariables that would otherwise confound the relationship
etween treatment variables and economic outcomes (von
inke et al., 2016).
On the other hand, the increasingly large scale of genetic
ata sources is beginning to reveal patterns of associ-
tion with environmental confounds, including patterns
f geographic settlement within otherwise apparently
omogenous ethnic populations, that cannot be eliminated
r “adjusted away” by using the types of control for pop-
lation structure that were implemented in our analysis
odels (Haworth et al., 2019). This is potentially problem-
tic; in the specific example of geographical similarity since
ultural, economic and other factors may  also differ by loca-
ion and could constitute omitted variables that confound
he associations we study.
An important analysis alongside our “population”-
ased main analysis is therefore that of within-family
nalysis – we provide more details below. This was com-
lemented by a range of other sensitivity analyses. The
rst considered whether the association between BMI  and
ealthcare cost may  be non-linear, the second estimated
 multivariable Mendelian Randomization instrumenting
or both BMI  and body fat percentage, the third assessed
hether results were robust to potential weak instrument
ias, the fourth examined a gene-environment interaction
s a means of identifying and correcting for pleiotropy
Chen et al., 2008; Davey Smith, 2010; Spiller et al., 2018),
nd the fifth considered a disaggregation of the cost out-
ome.
.3.1. Within-family Mendelian Randomization
Within-family Mendelian Randomization is intended to
ddress biases from dynastic effects (Brumpton et al., 2019;
letcher, 2011), but may  also avoid biases caused by cryptic
opulation structure not accounted for by restricting anal-al of Health Economics 70 (2020) 102300 7
ysis to homogenous ethnic groups and the use of genetic
principal components. Dynastic effects refer (in the present
context) to the direct effect of parents’ BMI  on their chil-
dren. This type of effect may reflect non-transmitted alleles
– even if children do not receive a BMI-increasing SNP,
their parents may  possess such a SNP and this in turn can
influence the environment in their children are raised. If
present, the main Mendelian Randomization analysis pre-
sented here would wrongly attribute some of the influence
of parental BMI  to the child’s BMI-increasing SNPs that are
included in the analysis. We  therefore explored whether
bias from dynastic effects could be reduced by conduct-
ing a within-family Mendelian Randomization in which a
family “fixed effect” adjusts for environmental conditions
created by parents that are shared by offspring (Pingault
et al., 2018).
Siblings were identified in the UK Biobank by using data
on kinship taken from the KING toolset and data on the pro-
portion of loci shared between individuals. More details are
available in Brumpton et al. (2019). We  restricted analysis
to the IVW estimator. This is because the MR-Egger, median
and mode estimators used in the main analysis on the sam-
ple of unrelated individuals have lower power than the IVW
estimator. The sample of included related individuals is less
than 10% (n = 28,608) of that used in the main analysis, and
the statistical power of IVW methods is therefore much
reduced.
We estimated fixed effect instrumental variable models,
clustering on family units, and conditioning on sex. Family
fixed effects control for time-invariant unobservable char-
acteristics that are specific to each family. We compared
the results of these models to those obtained from within-
family models that excluded the family fixed effect but
clustered standard errors at the level of the family.
2.3.2. Non-linear models
There is some evidence of a non-linear association
between BMI  and hospital costs from multivariable and
causal studies (e.g. (Cawley and Meyerhoefer, 2012; Cawley
et al., 2015b)). Fitting non-linear models in the IV settings
is complicated when the instruments explain a relatively
small proportion of variance in the treatment (as in the
present example), because any non-linear effects may not
be detectable in the relatively narrow range over which
such effects influence the treatment-outcome association
(Staley and Burgess, 2017b). This can be seen from com-
paring mean BMI  in individuals with the lowest decile of
the allele score (26.3 kg/m2) to those in the highest decile
(28.5 kg/m2).
To avoid this, we  used methods developed by Staley
and Burgess (Staley and Burgess, 2017a). This approach
proceeds from the observation that stratifying on the BMI
distribution by dividing it into categories or quantiles over
which the non-linearity can be assessed would violate the
exclusion restriction. This is because the premise of IV anal-
ysis is (in the present context) that BMI  is an intermediate
step on the causal pathway between the IV and the cost out-
come. BMI  is therefore a potential outcome of both the IV
and of the outcome, since hospitalisation itself may  affect
BMI, and naïve stratification on BMI  would represent over-
l. / Journ8 P. Dixon, W.  Hollingworth, S. Harrison et a
adjustment by inducing an association between the IV and
the outcome in violation of the exclusion restriction.
The starting point for this analysis was therefore to cal-
culate residual BMI. Residual BMI  is the difference between
BMI  and the fitted values obtained from a regression of BMI
on the weighted allele score. Residual BMI  for an individual
is therefore predicted BMI  for a (hypothetical) individual
with no BMI-increasing alleles. The study cohort was then
divided into 100 quantiles of residual BMI.
The (linear) Mendelian Randomization approaches
described above were then conducted within each quan-
tile, to give quantile-specific “local average causal effect”
estimates. These can be interpreted as the average change
in costs, within that quantile of the residual BMI  distribu-
tion, for a one-unit increase in genetically predicted BMI.
This results in 100 local average causal effects. These effects
were combined into a plot of local average causal effects
for 100 quantiles to compared against the corresponding
quantiles of the original BMI  distribution.
Meta-regression was then applied to these effect esti-
mates. Meta regression, in this context, assesses the extent
to which differences or heterogeneity between these local
average causal effects can be related to differences in BMI.
Absence of heterogeneity would indicate similarity of the
causal effect of BMI  on costs across the distribution of BMI
and provide evidence in support of linearity. Meta regres-
sion was implemented by estimating fractional polynomial
models of degrees 1 and 2. This permitted a fractional
polynomial test, which tests whether linear or non-linear
models offer a better fit to the data. A trend test was also
used, which regressed the local average causal effect esti-
mate on mean BMI  in each quantile.
2.3.3. Multivariable Mendelian Randomization – BMI
and body fat
Multivariable Mendelian Randomization can estimate
the direct causal effect of more than one treatment vari-
able (Burgess et al., 2014; Burgess and Thompson, 2015b).
In this application of multivariable Mendelian Random-
ization, genetic variants for BMI  and for percentage of
body fat were included in the same instrumental variable
model. This allows for these biologically related treatments
to be modelled together, and for the potential mediation
of one treatment (BMI for example) by another (body fat
percentage) to affect the outcome. The coefficients in the
estimated models reflect the direct causal effect of each
treatment, holding the other treatment fixed. These mod-
els have considerably lower power to detect causal effects
than univariable Mendelian Randomization, but the anal-
ysis can nevertheless usefully estimate the direct effect
of BMI  on outcome compared to the total (comprising
the direct effect of BMI  and its indirect effects via body
fat percentage) estimated in conventional Mendelian Ran-
domization (Sanderson et al., 2018). For the purposes of
comparison, we also estimated models utilizing percentage
of body fat only.
For this analysis we remain agnostic as to which of the
two measures of adiposity that we study below- BMI  and
percentage of body fat – more accurately index the health-
compromising consequences of fatness. The percentage of
body fat arguably better captures body composition thanal of Health Economics 70 (2020) 102300
does BMI  and may  better predict particular health out-
comes (e.g.(Burkhauser and Cawley, 2008; Kragelund and
Omland, 2005; Yusuf et al., 2005)), but BMI  nevertheless
retains broad applicability and utility as an easily measured
variable that offers robust associations with a variety of
relevant health outcomes (Corbin and Timpson, 2016).
2.3.4. Weak instruments
We estimated the “robust adjusted profile score” model
of Zhao et al. (2018), which is unbiased in the presence of
many weak instruments, and is also robust to measurement
error in SNP-treatment estimates. The Zhao et al. approach
relies on a version of the InSIDE assumption that underpins
the MR-Egger approach, but unlike MR-Egger assumes that
the pleiotropic effects ˛1, ˛2, . . .˛k have mean zero.
Our use of this model is conservative, since we use
only genome-wide significant SNPs from the Locke et al.
(2015) BMI  genome wide association study. Neverthe-
less, we  report it as an additional sensitivity analysis. If
our instruments are weak, we would expect to observe
a large difference in the causal estimate between the
robust adjusted profile score and our base inverse variance
weighted estimates.
2.3.5. Gene-by-environment interaction
We considered gene-by-environment interactions as a
means of detecting and correcting for pleiotropy. If an
instrument (such as a BMI  SNP or set of SNPs included
in an allele score as described below in Section 3.3) inter-
acted with a covariate induces variation in the association
between the instrument and the BMI  treatment variable,
it is possible to identify and correct for pleiotropic effects.
This approach builds on work (Cho et al., 2015) (Slichter,
2014) that considers a no-relevance population subgroup
for which instrument and treatment variables are indepen-
dent.
In the context of Mendelian Randomization, an
instrument-outcome association for a no-relevance sub-
group would indicate the presence and extent of
pleiotropy, which could then be subject to bias correction.
This is because SNPs that are valid IVs can only influence
the healthcare cost outcome by their effect on BMI. This
approach is set out in Spiller et al. (2018), which does not
depend on the existence of an observed no-relevance sub-
group, and in essence places the IV assumptions on the
interaction between the IV and the covariate, rather than
solely on the IV.
We modelled an interaction between the BMI  IV and
socio-economic deprivation, and separately between the
BMI  IV and participant age. Deprivation reflects access to
material goods (such as car ownership), occupational sta-
tus and education level. We  note that, for both the BMI
IV-deprivation and BMI  IV-age estimates to be valid, it is
necessary to assume that pleiotropic effects do not differ
between the population subgroups.
2.3.6. Type of outcome
We also assessed whether any heterogeneity present
in the main analysis was  also present when disaggre-
gating overall inpatient hospital costs into elective costs,
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efinitions of these terms and the analysis undertaken is
rovided in supplementary material.
. Data
.1. UK biobank
Individual-level data were drawn from the UK Biobank
tudy. This very large, high quality prospective cohort
nrolled 503,317 adults (representing a response rate of
pproximately 5.5%) aged between 37 and 73 (99.5% of
nrollees were aged between 40 and 69) living in Eng-
and, Scotland and Wales (Fry et al., 2017). Invitations to
articipate were issued to all eligible adults. However, par-
icipation itself was not random, with the consequence that
he Biobank cohort is not representative of the wider pop-
lation from which it is drawn. In particular, the cohort is
ealthier (Sudlow et al., 2015) (lower levels of mortality
nd lower rates of morbidity-increasing behaviour such as
moking) and is better educated (Fry et al., 2017) than the
ider UK population.
At the baseline appointment, participants completed
 number of questionnaires, biomarker specimens were
rawn, physical function was assessed, and consent was
iven to link these data to death registers and healthcare
ecords (Sudlow et al., 2015). Deprivation was calculated
sing the Townsend Deprivation Index and divided into
uintiles when treated as a covariate in the Spiller et al.
2018) gene-by-environment sensitivity analysis described
bove.
Weight and height were measured at the baseline
ppointment by nurses. Weight was measured using
eighing devices. Body composition was measured using
io-impedance (opposition of alternating current to adi-
ose tissue). Both measures were very similar (Lin’s rho
-value <0.001) and impedance-based BMI  data were used
hen the conventional BMI  data were missing. Observa-
ions that had a mean difference between traditional and
mpedance-based measures of BMI  of more than 5 stan-
ard deviations from the mean difference were excluded
rom the analysis. Whole body percentage fat mass cal-
ulated from impedance measurements was used in the
ultivariable Mendelian Randomization analysis.
.2. Measurement of costs
The hospital care that we measure was provided by
ospitals operating under the aegis of the National Health
ystem (NHS) in England and in Wales. The NHS is a tax-
ayer funded provider of universal healthcare. In principle,
here are no relevant differences in access by eligible indi-
iduals to NHS services by region or other characteristics.
n practice, there may  be modest differences in access to
ospital care, such as slightly longer waiting times for treat-
ent in some areas, but these are unlikely to be relevant
o the methods or conclusions of this study.
The hospital costs that we analyze are those borne by theHS as a public provider of universal health care. The data
e access is not a sample of hospital care episodes; instead
t is a census that captures the universe of all inpatient
are in these hospitals. This encompasses both publiclyal of Health Economics 70 (2020) 102300 9
funded care provided in NHS and private hospitals, as well
as privately funded care (arranged through private health
insurance, for example) that is performed in the public hos-
pital system. Thus, the coverage of hospital costs accounts
for all publicly funded care but does not include care in pri-
vate hospitals that is not arranged and funded by the NHS,
data for which is not available for the UK Biobank cohort.
Admitted patient care episodes, sometimes referred to
as inpatient care episodes, were obtained from Hospital
Episode Statistics (HES) (for English care providers) and
from the Patient Episode Database for Wales (for Welsh
providers) that were linked to UK Biobank. Inpatients are
those admitted to hospital and who occupy a hospital bed
but do not necessarily stay overnight (i.e. day case care).
Due to differences in the collection and valuation of care in
Scottish hospitals compared to hospitals in England and
Wales, only costs from the latter two jurisdictions are
included in this analysis. Linkages to other forms of care
were not available at the time of writing.
Each “Finished Consultant Episode” (FCE) on inpatient
care can be characterized by a number of variables, most
importantly procedure codes and diagnosis codes (based
on ICD-10 codes (World Health Organization, 1992)). These
FCEs were converted, using NHS software (NHS, 2016), into
Healthcare Resource Groups (HRGs). HRGs are used for
casemix-adjusted remuneration of publicly-funded hospi-
tals in England and Wales. Unit costs were assigned to each
HRG, and inpatient costs per person year of follow-up were
calculated for each patient on the basis of their recorded
FCEs (if any). Further details on the cost calculations are
given in Dixon et al. (2018).
Only episodes and UK Biobank baseline appointments
occurring on or after 1 April 2006 were eligible to be
included in the analysis because of changes to the hos-
pital payment system that came into effect at that time
(Department of Health, 2012). Data on inpatient episodes
was available until patient death, patient emigration (rates
of which are estimated to be a modest 0.3% (Fry et al.,
2017)), or the censoring date for inpatient care data of
31 March 2015. Cost data are reported in 2016/17 pounds
sterling.
Hospital cost data is often skewed and individuals who
did not report hospital use have no hospital costs. Despite
these features being present in our hospital data, we  used
the Mendelian Randomization estimators (inverse vari-
ance weighted, MR-Egger, penalized weighted median and
weighted mode) described above to analyze these data for
two reasons. The first is that instrumental variable models
still produce a policy-relevant average causal effect esti-
mate of the association between BMI  and healthcare costs
even if this association is non-linear.
The second argument, based on Zhao et al. (2018), is that
SNPs explain a modest proportion of the variance in the
outcome via the treatment variable. In our case, any dif-
ference induced by the SNPs in the BMI  treatment variable
therefore only requires the assumption of linearity over a
small range, and this assumption will hold to a satisfac-
tory approximation whenever the function is differentiable
over that range – the full logic behind this claim is set out
in supplementary material.
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We  can use this logic to map  out the shape of the rela-
tionship by examining these associations over quantiles
of the BMI  distribution. We  can use techniques for non-
linear instrumental variable analysis to make claims about
the similarity or otherwise of the causal effect of BMI  on
healthcare costs at different quantiles of the BMI  distri-
bution (Staley and Burgess, 2017a). This is the same set
of techniques that we use model and test for non-linear
effects as described above.
3.3. Genetic data and linkage to phenotypic data
Genetic data was subject to quality controls by UK
Biobank, as well as further in-house processing and man-
agement (Harrison, 2019; Mitchell et al., 2017). Briefly,
488,377 individuals in the UK Biobank were success-
fully genotyped. Removal of individuals was performed
as follows: sex mismatches and individuals with abnor-
mal  numbers of sex chromosomes, related individuals, and
those who withdrew consent. To avoid biases from popula-
tion stratification, the sample was restricted to individuals
of white British ancestry (as determined by self-report or
analysis of genetic principal components (Bycroft et al.,
2018)). Bringing together all the genetic and phenotypic
data, including the cost data necessary to calculate IV mod-
els, resulted in 307,048 individuals included in the analysis.
Further detail on these steps is provided in the Supplemen-
tary Material. Related individuals were analyzed separately
for the within-family Mendelian Randomization analysis.
The most recent and largest genome-wide associa-
tion study of BMI  that did not explicitly overlap (Yengo
et al., 2018) (i.e. include individuals who appeared in both
the genome-wide association analysis sample and the UK
Biobank sample) was Locke et al. (2015). Proxy SNPs were
used for any SNPs identified in Locke et al. (2015) but not
present in UK Biobank, provided that a suitable proxy with
an R2 statistic between the proxy and missing SNPs of at
least 0.8 was available in UK Biobank. To avoid violations
of the IV assumptions due to linkage disequilibrium, only
SNPs that were correlated with each other with an R2 of less
than 0.001 within 10,000 kilobases were retained for anal-
ysis using the MR-Base R package (Hemani et al., 2018b).
In total, 79 of the 97 genome-wide significant SNPs identi-
fied in Locke et al. (2015) were included in the analysis,
following this process and the removal of triallelic and
unreconciled palindromic SNPs. SNP data were harmonized
between Locke et al. and UK Biobank so that each source
corresponds to the same allele.
Locke et al. includes groups of heterogenous ancestry
(Berg et al., 2018). The list of 79 SNPs from Locke et al.
included those from studies of both European and non-
European ancestry. In sensitivity analysis, we  re-ran the
Mendelian Randomization analysis restricting the SNPs
(n = 69) from Locke et al. that were discovered using indi-
viduals of European ancestry only. The restriction of the
set of SNPs to those identified as genome-wide significant
in the Locke et al. GWAS was intended to test the sensi-
tivity of the results to greater homogeneity between the
two samples used, at the cost of a possible reduction in
power. Power may  be lower because of the smaller num-
ber of SNPs used, and a possible reduction in the proportional of Health Economics 70 (2020) 102300
of variance in BMI  that these SNPs explain. However, power
would not have reduced relative to the base case if these
SNPs only affected people of non-European origin. Data on
SNPs implicated in fat mass percentage used in multivari-
able analysis were taken from Lu et al. (2016).
Both the individual variants and a summary polygenic
allele score created from these variants were used in analy-
sis. The allele score was used in tests of association between
potential omitted variables present at conception that were
available in UK Biobank (sex, year of birth, month of birth)
using linear regression. The allele score was  calculated as
the sum of the BMI-increasing alleles for SNPs attaining
genome wide significance in Locke et al. (2015). Each SNP
was  weighted by the size of its effect on BMI.
We  compared the Mendelian Randomization estimates
to those from multivariable conditional correlational mod-
els by estimating the effect of a marginal unit of BMI on
costs using ordinary least squares models and a gener-
alized linear model with a gamma  family and log link
function following Dixon et al. (2018).3 In these models
we  controlled for sex, days of exercise, frequency of alco-
hol consumption, educational qualifications, employment
status, quintiles of deprivation, and age at recruitment to
the UK Biobank cohort. We assume for both the OLS mod-
els and the generalized linear models that none of these
controls are potential outcomes of both BMI  and of the cost
outcome.
The causal estimates from the Egger, median and mode
estimators were converted from standard deviation units
of BMI  reported in the Locke et al. (2015) to natural units
of BMI  by dividing by the median standard deviation of
BMI  (4.6) in that study, as reported in Budu-Aggrey et al.
(2018). This rescaling allows the results of all estimators
to be interpreted as the marginal effect of a unit (kg/m2)
increase in BMI  on inpatient costs.
Analysis was conducted primarily in R using the MR
Base package (Hemani et al., 2018b). Stata version 15.1
(StataCorp, College Station, Texas) was used for some
elements of the analysis. Analysis code is available at
github.com/pdixon-econ
4. Results
Of the 307,048 individuals included in the analysis
sample, 54% were female (n = 164,903), and mean age
was  56.9 years (standard deviation: 8.0). Mean BMI  was
27.4 kg/m2 (a histogram of BMI  is provided in supple-
mentary material). Some 55% (n = 168,486) of patients
had positive inpatient hospital costs. Mean and median
follow-up of inpatient hospital data was  6.1 years. The
most common ICD-10 chapters under which patients were
admitted (other than for symptoms and findings not oth-3 The estimated effect of a marginal unit BMI  differ between those
reported in Dixon et al because the sample here is restricted to those
with valid genetic data
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Table  1
Mendelian Randomization and multivariable estimates of marginal effect
of an additional unit of BMI  on per person year inpatient hospital costs.












Note: We  report p-values smaller than 0.001 as <0.001. Larger p-values
are reported to two  decimal places.
Table 2
Results of primary Mendelian Randomization models.
Beta (£) SE P-value
Estimator
IVW RE (for reference) 21.22 3.50 <0.001
MR-Egger 7.41 8.44 0.38
Penalized weighted median 18.85 5.00 <0.001



































Mendelian Randomization results by sex.
Beta (£) SE P-value
Estimator
Males
IVW RE 23.21 4.78 <0.001
MR-Egger 14.21 11.67 0.23
Penalized weighted median 24.45 7.94 <0.001
Weighted mode 25.34 9.89 0.01
Females
IVW RE 19.64 4.16 <0.001
MR-Egger 2.16 10.05 0.83
Penalized weighted median 12.01 6.72 0.07
Weighted mode 8.86 8.02 0.27ote: We  report p-values smaller than 0.001 as <0.001. Larger p-values
re reported to two  decimal places.
Mean inpatient hospital cost per person-year of follow-
p was £479, while median costs were £88. There was
vidence of association of the BMI  allele score with nine
f the first ten principal components (largest p-value, from
he eighth principal component = 0.11)) and weaker evi-
ence of association with month (p = 0.46), year of birth
p = 0.07) and sex (p = 0.06). Sex and all ten principal com-
onents were included as covariates in all Mendelian
andomization models. The F-statistic from the first stage
f a two-stage least squares model using the BMI  allele
core as an instrumental variable was 697, and the same
tatistic was measured as 96 when including all 79 SNPs
s individual instrumental variables in the same type of
odel.
Results indicate that the effect of an additional unit of
MI  is approximately 58% higher using IVW methods than
nder multivariable generalized linear analysis and 48%
igher than the ordinary least squares estimate (Table 1).
However, there is evidence of heterogeneity (Cochran’s
 = 107.8, p-value for null of no heterogeneity = 0.01) in the
ase IVW results, one cause of which may  be pleiotropy
n violation of the exclusion restriction. Heterogeneity is
pparent in the forest plot (Fig. 1). A forest plot without
eterogeneity would show all variants “lining up” around
he same point estimate of effect, subject to sampling vari-
tion which will mean that not all variants would lie on
recisely the same line.
The results of MR-Egger and other methods to adjust for
leiotropy are indicated in Table 2, presented for compar-
son alongside the base IVW results.
All estimators identify a positive effect of BMI on hospi-
al costs, although the MR-Egger estimates are imprecise.
ig. 2 presents a scatter plot summarising the results from
he four estimators presented in Table 2. Results from mod-
ls that also conditioned on age were similar – details are
rovided in supplementary material.Note: We report p-values smaller than 0.001 as <0.001. Larger p-values
are reported to two  decimal places.
The MR-Egger Cochran’s Q test of heterogeneity was
103.44 (p-value 0.02) and the intercept of this model was
estimated as £1.93 (standard error: 1.07, p-value: 0.08).
The IVW effect estimate is larger than all other estimates,
although similar to the penalized weighted median esti-
mate. If pleiotropy is present in the IVW model but not
in the penalized weighted median model, it appears to be
inflating the effect estimates, which would be the case if
some of the included SNPs act on other conditions or traits
that tend to increase inpatient costs on average.
The InSIDE assumption, which must be satisfied for
MR-Egger estimates to be unbiased, is most likely to hold
where the violations of the IV assumptions are caused by
pleiotropy that does not influence omitted variables in the
BMI-cost association. The rationale for this position was
discussed in the Methods section above. In practice, there
is probably good reason to suspect violations of this type, as
any variant that influences, for example, mental health may
well be an omitted variable that independently influences
both BMI  and inpatient costs. In the case of this hypo-
thetical example, instrument strength (measured by the
association of BMI) may  be correlated with a direct effect
of the SNP (via mental health) on the cost outcome. Thus,
any SNP included amongst the 79 here that causes people
to have inpatient care may  well induce violations of InSIDE.
It is notable that the median and mode estimators are
reasonably similar, despite the differences in the assump-
tions underlying each method. This is suggestive evidence
that a similar causal effect is perhaps being identified by
these two  methods.
Evidence for heterogeneity is less apparent when strati-
fying on sex (Table 3). Evidence of heterogeneity was weak
when estimating separate models for men  and women
(Cochran’s Q: males: Q = 82.71, p-value = 0.33; females:
Q = 92.05, p-value = 0.13.) Effect sizes were larger for males
than for females, although confidence intervals overlapped
for all estimators (Fig. 3).
For the within-family analysis, 28,608 individuals were
observed in 13,838 family units.
The estimated effect of an additional unit of BMI  was
£16.42 (standard error 19.10, p-value 0.39) in within-
family Mendelian Randomization models controlling for
sex (but not genetic principal components). The effect size
estimated is similar but slightly smaller than in all other
analyses but is very imprecisely estimated.
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Fig. 1. Forest plot of SNPs.
Note:  This table lists effect sizes and 95% confidence intervals for all 79 SNPs, ordered according to positive effect size on the outcome. The two  diamonds
Ps (“All
en usinat  the bottom of the plot represent the IVW estimate from using all SN
the  MR-Egger estimate (“All – Egger”) with a 95% confidence interval wh
associated with much greater uncertainty that the IVW estimate.
The same model estimated without family fixed effects,
controlling for sex again without genetic principal compo-
nents) and clustering standard errors at the family level
was also consistent with the null with a similar effect size
(£11.96, standard error 10.38, p-value = 0.25). Both esti-
mates are similar to each other in having point estimates
lower than the base case estimates, and are both very
imprecisely estimated, with standard errors similar to the
absolute size of the point estimate.
These results differ from our main analysis in some-
what smaller effect sizes, which may  indicate that dynastic
biases are inflating estimates in our population wide “unre-
lated” sample used for the main analysis. However, these
results are also very imprecise, and power to reject the
null in this sample is weak, given that the sample used
in the main analysis is more than ten times larger, and
that the included SNPs happen to explain less of the varia-
tion in BMI  (see below). This suggests null results from the
within-family models may  be a false negative associated
with weak statistical power in the within-family sample.
Evidence from Kong et al. (2018) suggests that the effect
size of non-transmitted BMI-increasing alleles is smaller
than the effect size for transmitted alleles (as modelled in
the main analysis), which is another consideration to sug-
gest that dynastic effects may  not be a large source of bias
in this context. – IVW”) together with a 95% confidence interval, and also for contrast
g all 79 SNPs. Point estimates are positive in each case, but MR-Egger is
Differences between the within-family and unrelated
samples also complicate interpretation of our findings. The
within-family sample differed from the sample of unre-
lated individuals in relation to the proportion of females
(57.8% versus 53.5%), mean cost (£600 versus £479) and
mean age at recruitment (57.6 versus 56.9 years); p < 0.001
for the null of no difference for all of these comparisons. The
relationship of the 79 SNPs to BMI  also differed between
samples – these SNPs explained 1.74% of the variance in
the unrelated sample but only 1.64% in the within-family
sample.
However, mean BMI  (p = 0.07) and mean BMI  allele score
(p = 0.45) were similar between the within-family sample
and the sample of unrelated individuals. There was no dif-
ference in the size of the absolute effect of the SNPs on BMI
in any sample, whether measuring this as a within-family
effect, treating siblings as individuals, or on the sample
of unrelated individuals. The estimated effect of the allele
score on BMI  was close to 4.0 in each specification (i.e. each
unit increase in the allele score increases BMI  by 4 units),
obtained using simple linear regression models controlling
for sex, except for the within-family estimates which were
implemented using a fixed-effects model.
Along with dynastic biases, we  also cannot completely
rule out other explanations for our findings, especially
those that would give rise to a non-random distribution of
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Results of multivariable Mendelian Randomization analysis.
Beta (£) SE P-value
Genetic variants
IVW RE of total effect of BMI
only (for reference)
21.22 3.50 <0.001
BMI  22.40 9.12 0.01
Body fat percentage −2.75 13.31 0.84ig. 2. Scatter plot and effect estimates for four main estimators.
ote:  All 79 SNPs are plotted together with 95% confidence intervals rep
vertical axis).
lleles in the population, due to assortative mating or resid-
al population stratification. We  consider the meaning and
mplications of these terms below in the Discussion.
Overall, larger sample sizes, potentially involving meta-
nalysis across cohorts where within-family Mendelian
andomization is possible, would provide the best means
o definitively understand whether statistical power, dif-
erences between within-family and unrelated samples, or
ubstantive dynastic or other biases explain our results
rom within-family models. We  cannot eliminate dynastic
ffects as a possible source of bias in our analysis.
.1. Other sensitivity analyses
Using the full base case sample of unrelated indi-
iduals, there was little evidence of non-linearity. There
as evidence consistent with the null for a quadratic
erm (p = 0.88), for differences in local average treatment
ffect estimates across quantiles (p = 0.15), for heterogene-
ty in the associations between the instrument and BMI
cross quantiles (p = 0.26) but some evidence of a linear
rend in the association between the instrument and BMI
cross quantiles (p = 0.03). We  conclude that the associ-
tion between adiposity and inpatient hospital costs for
his sample is approximately linear. This association is pre-
ented graphically in the supplementary material.
There was modest attenuation of the effect of BMI  on
osts when including body fat percentage in a multivariableNote: We report p-values smaller than 0.001 as <0.001. Larger p-values
are reported to two  decimal places.
Mendelian Randomization analysis. The causal coefficient
on the body fat percentage IV was  consistent with the null,
while the effect estimate on BMI  was  within the confidence
intervals of the base IVW estimate (Table 4).
In a Mendelian Randomization analysis using body fat
percentage only the IVW effect estimate was  consistent
with null (£10. 76, SE 8.15, p-value = 0.18) per additional
percentage point of body fat. However, there was  evidence
of heterogeneity (Q = 32.58, p-value<0.001). MR-Egger esti-
mates were also null (£18.14, SE 40.17, p-value = 0.66), but
the other pleiotropy-robust estimates suggested point esti-
mates for a one percent increase in body fat that were
broadly similar to (if slightly higher than) those estimated
for an additional unit of BMI. The penalized weighted
median estimate was  (£22.05, SE 6.97, p-value = 0.001)
and the weighted mode estimate (£23.11, SE 8.18, p-
value = 0.02).
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Fig. 3. Mendelian Randomization results overall and by sex.
Note:  Each dot represents a point estimate, together with a 95% confidenc
Overall, this suggests that any direct effect of body
fat percentage on hospital costs is limited, and body
fat percentage probably does not mediate the effects
of body mass index on hospital costs. If body fat per-
centage were a mediator, the causal effect of BMI
would change much more markedly between the con-
ventional and multivariable Mendelian Randomization
analyses. Pleiotropy-robust estimates for both BMI  and
body fat percentage indicated a causal effect on hos-
pital costs that were or roughly similar magnitude,
albeit body fat percentage estimates were somewhat
higher.
Application of the robust adjusted profile score method
of Zhao et al. (2018) (to assess possible impacts of weak
instrument bias) did not substantially alter the base IVW
estimates of the causal effect, estimating a causal effect
per additional unit of BMI  of £21.69 (standard error 3.06,
p < 0.001) compared to the base IVW estimate of £21.22
(standard error 3.50, p < 0.001). Subject to the assumptions
of the method, particularly that all pleiotropic effects haveal, corresponding to the results in Tables 2 and 3.
mean zero, this suggests that weak instruments and mea-
surement error in the SNP-treatment association are not
likely to be material sources of bias, at least for the base
case results.
The results of the gene-by-environment test, in which
the BMI  allele score was interacted with deprivation as
a means of detecting and correcting for pleiotropy, were
imprecise. Although the Spiller et al. (2018) method did
identify a positive effect of BMI  on healthcare costs (£12.69,
standard error 5.44), this estimate was  consistent with
the null (p-value = 0.10). Note also that these estimates
lie within the confidence interval for the MR-Egger esti-
mates, which may  reflect a lack of precision to identify a
robust directional pleiotropic effect in these two  analyses.
The null result for the gene-by-environment test may  also
reflect a violation of the constant pleiotropy assumption
in this sample, in which the magnitude of the pleiotropic
effect is not the same across levels of deprivation. Imprecise
results were also obtained when interacting the allele score
with quintiles of age, although the magnitude of the effect
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Table  5
Results of all Mendelian Randomization models with restricted SNP list.
Beta (£) SE P-value
Estimator











































MR-Egger 6.47 11.02 0.56
Penalized weighted median 16.10 5.03 0.001
Weighted mode 7.48 8.41 0.38
iffered in size and sign (-£12.13, standard error = 6.59, p-
alue = 0.16)
Models using a set of SNPs derived from using SNPs
enome-wide significant for those only of European ances-
ry indicated lower effects sizes and greater differences
etween the median and mode estimators (Table 5). These
odels have somewhat lower power than the base mod-
ls, but this may  not explain more than a small part of the
ttenuation of effects observed.
Heterogeneity was also somewhat lower when using
he restricted list of SNPs, with Cochran’s Q for the
VW model of 88.32 (p-value = 0.04). This suggests that
leiotropy (amongst other reasons) may  be less impor-
ant for these results than for the main results, and it is
otable that the IVW RE estimates become closer to those
f the pleiotropy-robust base case estimates. This may  also
xplain the divergence between the penalized weighted
edian and weighted mode estimates that is apparent in
able 5, although we have no way of testing this.
Finally, we considered disaggregation of all costs into
lective costs, non-elective costs and other costs. Detailed
esults are provided in supplementary material. The largest
bsolute effect of BMI  appears to be on elective care
osts, for which estimated heterogeneity (as measured by
ochran’s Q) was similar to that for overall aggregate costs.
hile suggestive, caution is required in interpreting these
esults. First, the categorizations used are somewhat arbi-
rary. Second, comparing the disaggregated costs both to
ach other and to all costs involves comparing different
roups of individuals, since some cohort members report
osts only in one subcategory of costs.
. Discussion
The long-established positive association between adi-
osity and hospital costs appears to be causal. The results
resented here using a novel Mendelian Randomization
ethodology suggest that this effect of a marginal unit of
MI  is higher than that suggested by conventional multi-
ariable analyses.
Below, we consider the choice of a preferred model of
ll of those estimated. We  then compare our findings to the
iterature, consider the generalizability of these findings,
iscuss potential remaining biases and conclude with an
ssessment of the policy relevance of our work.
.1. The choice of a preferred modelWe  start our discussion of a preferred set of estimates
ith consideration of statistical power. Given the complex-
ty of BMI  as a trait (many SNPs contribute to BMI), and
iven that effect sizes of individual SNPs are modest at best,al of Health Economics 70 (2020) 102300 15
very large sample sizes are required to obtain sufficient sta-
tistical power to avoid the risks of (a) falsely failing to reject
a null hypothesis (b) overstating effect sizes when the null
is not rejected.
Some of the estimators had relatively low power to
reject the null hypothesis. The MR-Egger regression had
lower power than the other population-based methods
(as opposed to within-family methods) because it esti-
mates twice the number of parameters than these other
methods in estimating both an intercept (which is used
to test and adjust for any pleiotropy) and the slope esti-
mate (which measures the combined causal effect of all
SNPs). The Spiller gene-by-environment method (Spiller
et al., 2018) was  also imprecise; this approach has lower
power than other methods (in part) because it estimates
an interaction term.
Our within-family analysis may  be affected by low sta-
tistical power. In addition to the within-family fixed effect
models, the sibling sample without family fixed effects was
also imprecise.
Imprecise estimates from our within-family analysis
represent an important contextual finding for the interpre-
tation of our main results but do not oblige us to discard or
discount the results from the population-wide Mendelian
Randomization estimators.
Estimates derived from well powered sources – inverse
variance weighted estimators, median-based estimators,
and mode-based estimator – rejected the null, and sug-
gested that the BMI  has causal effects on hospital costs.
Taking this into account, and given the evidence of
pleiotropy that may  have affected the inverse variance
weighted estimators, we  conclude that the penalised
weighted median and the weighted mode estimators are,
potentially, the most reliable guides to the effect of the
marginal unit of adiposity on hospital costs in the sample of
unrelated individuals. However, larger within-family mod-
els would offer the most compelling source of evidence.
5.2. Comparison with other findings
Estimated differences between IV and adjusted mul-
tivariable models are smaller than those obtained from
analyses using biological relatives as instruments, albeit
these other studies were conducted on samples that may
differ quite markedly from the sample studied here. Stud-
ies by Black et al. (2018a) on Australian data, Kinge and
Morris (2018) on UK data and Doherty et al. (2017) on Irish
data are studies on children and adolescents. The Black et al.
(2018a) study specifically excludes inpatient costs. Doherty
et al. (2017) measure resource utilization in primary care
and inpatient hospital stays rather than healthcare costs.
Cawley et al Cawley et al. (2015b) specifically focuses on
BMI  impacts in relation to diabetic status. Nevertheless, all
studies find that conventional research designs and esti-
mators (such as OLS) suggest lower effect sizes than those
from instrumental variable models. This is also a feature of
our Mendelian Randomization estimates.The study with the most similar outcome measure for
an adult population is probably that of Cawley and Mey-
erhoefer (Cawley and Meyerhoefer, 2012), who provide
estimates of the effect of the marginal unit of BMI  on inpa-
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tient hospital costs in their US sample ($54, 2005 price
levels). The average closing price of US dollars to ster-
ling during 2005 was 1.82 dollars to one pound sterling
(Macrotrends, 2019), making the marginal unit in 2005 in
the Cawley and Meyerhoefer sample worth approximately
£29.67, or £36.51 in 2016/17 pounds sterling (adjusting for
inflation using the GDP deflator (HM Treasury, 2019)). This
figure is drawn from a different health system with a differ-
ent population to UK Biobank (being less selected and likely
to be more representative of the underlying population)
but nevertheless does indicate a very roughly comparable
magnitude of effect if one accounts for higher healthcare
costs in the US relative to the UK.
The above studies examine the effect of adiposity in dif-
ferent populations and contexts, but generally find a larger
difference between multivariable conditional correlation
estimates and IV models, in contrast to the smaller rela-
tive difference found in our study. One possible explanation
for a larger difference in effect sizes between these types
of estimators is attenuation bias, caused by measurement
error in the relative effect of BMI, which would tend to
inflate differences between multivariable and IV analysis,
since the multivariable results may  be biased downward.
UK Biobank estimates are based on high-quality indepen-
dent (i.e. not self-reported) measurements of weight and
height, whereas models relying on self-report BMI  may
exhibit more attenuation bias and thus exaggerate the dif-
ference between IV and non-IV results. This is speculative
but may  explain some of the difference in relative effect
sizes between our study and other findings in the litera-
ture.
More generally, there is a lack of a “gold standard”
against which to judge multivariable and IV models
or the various Mendelian Randomization estimators.
Methods are being developed to choose amongst MR
estimators including machine learning (Hemani et al.,
2017) and principled approaches to the treatment of
“outlier” SNPs (Cho et al., 2019), although a degree
of judgement and some contextual reasoning seems
unavoidable in interpreting Mendelian Randomization
analysis.
Despite the absence of a clear means to choose between
types of estimator, there seems to be grounds to argue
that policy evaluations and other quantitative analysis
requiring estimates of the marginal cost of a unit of BMI
should treat multivariable conditional correlation esti-
mates as a lower bound. Analysts should consider including
higher estimates of the cost of a marginal BMI  unit in pri-
mary empirical analysis and undertake sensitivity analysis
that tests the robustness of conclusions to lower esti-
mates.
5.3. Generalizability of findings
Are the results from this analysis likely to be generaliz-
able to wider populations? Two issues merit consideration.
The first is whether the Mendelian Randomization esti-
mates are themselves helpful in understanding the effect
of BMI  on inpatient hospital costs. The second is whether
the particular features of the UK Biobank sample, which is
healthier and wealthier than the population from whichal of Health Economics 70 (2020) 102300
it is drawn (because of non-random participation), may
itself create bias. We  consider policy relevance separately
below.
On the first point, Mendelian Randomization methods
estimate, in this case, the effects on inpatient costs of a
lifelong exposure to BMI-increasing SNPs, rather than a
temporary or acute effect of higher or lower BMI. We  use
the term “lifelong” (Holmes and Smith, 2017) to refer to
the effect of genetic variation determined at conception
and assume that the association between the genetic vari-
ants and the relative effect of BMI  does not change with
age. The effect sizes estimated under all but the MR-Egger
Mendelian Randomization analyses were larger in mag-
nitude than the multivariable estimates, which suggests
that they may  reflect a cumulative exposure to higher BMI
(Holmes et al., 2017).
It is plausible that lifelong exposure to higher BMI,
randomly determined at conception, could manifest in
higher rates of inpatient admission and the use of more
complex and expensive treatments amongst the middle-
aged and early-old aged individuals represented in the
UK Biobank cohort. As BMI  is potentially modifiable, this
suggests that policies targeting reductions in BMI (where
clinically appropriate to do so) could reduce use of hos-
pital resources (amongst other impacts on morbidity and
mortality (Wade et al., 2018)).
The second issue concerning the generalizability of our
findings relates to the similarity or otherwise of the UK
Biobank cohort to the wider population, and the implica-
tions that any differences may  have on the generalizability
of the results presented here. Relative to the UK popu-
lation, participants in the cohort study had lower levels
of mortality (Sudlow et al., 2015), lower rates of health-
compromising behaviour, and are better educated (Fry
et al., 2017). BMI  and use of hospital resources may
themselves influence participation in the study (since
sicker individuals were less likely to participate), and
some degree of selection bias is possible (Hughes et al.,
2018b). This specific bias goes by different names, includ-
ing “collider bias” (Munafò et al., 2017; Spirtes et al.,
2000) and bias due to “bad controls” (Angrist and Pischke,
2009).
This selection appears to be problematic (in terms of
bias and Type 1 error rates) for Mendelian Randomiza-
tion only when selection effects are themselves particularly
large (Hughes et al., 2018a). Since the size of this effect will
generally be unknown (because the mechanism driving
selection is unknown) it is not possible to be defini-
tive about its scope in the present context. Gkatzionis
and Burgess (Gkatzionis and Burgess, 2018) suggest, on
the basis of their simulations, that selection in general
is probably less important as a source of bias than, for
example, violations of the exclusion restriction caused
by pleiotropy. It is also important to note that selection
will also affect the non-causal multivariable estimates of
a marginal unit of BMI  presented alongside the causal
IV analysis. It is possible that the precise figure for a
marginal unit of BMI  under either method may  differ in
other cohorts but nevertheless the ratio of the causal to
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.4. Potential remaining biases
Three potential remaining sources of bias may  be
resent in our main analysis due to assortative mating,
ryptic population structure, and cohort effects.
Assortative mating refers to departures from random
ating (Vandenberg, 1972) and may  affect our analysis of
nrelated individuals. The simulation and modelling study
f Hartwig et al. (2018) found that bias from assortative
ating would affect all forms of Mendelian Randomization
nalysis described above, including methods that attempt
o account for pleiotropic SNPs. Bias from assortative mat-
ng can overestimate SNPs-BMI and SNP-inpatient costs
ssociations. This bias is larger when the strength of non-
andom assortment is high, the outcome is highly heritable
nd when the process of non-random mating has been
resent for a number of generations. In the absence of data
elating to these influences, we simply note that this bias
ay be present to some extent in the results presented
ere for population-wide analysis but not for sibling mod-
ls, and that data on family trios (parents and offspring)
ould help assess if assortative mating was present.
Second, Mendelian Randomization analysis may be con-
ounded by cryptic geographic or population structure.
here is some evidence, for example, that geographic
tructure is present in the UK Biobank sample (Haworth
t al., 2019), which would re-introduce bias due to, for
xample, environmental omitted variables (Koellinger and
e Vlaming, 2019). This could bias associations between
ealth outcomes and genetic data. Our inclusion of genetic
rincipal components will address some but potentially not
ll such biases.
The third possible source of bias arises from cohort
ffects. Evidence from, for example, American sources
Rosenquist et al., 2015; Walter et al., 2016) indicates an
pparently greater effect of SNPs on BMI  for individuals
orn in more recent decades compared to those born in the
arlier part of the twentieth century. This phenomenon was
ttributed in these papers to an increasingly obesogenic
nvironment.
We cannot measure cohort effects separately from age
ffects since we do not have longitudinal evidence on
MI, which was not collected in Biobank for other than
 small subsample of individuals. This means we cannot
ully test the association of the allele score with BMI  by
ohort and by age. There was weak evidence of an associa-
ion between the allele score and participant age (p = 0.07),
nd Mendelian Randomization models conditioning on age
ere similar to those that were not conditional on age. If
ohort effects are present, however, then our effect esti-
ates may  underestimate the impact of a marginal unit
f BMI  on hospital costs both for younger cohort members
nd for individuals that were too young to be recruited into
K Biobank.
.5. Policy relevanceEstimates of the effect of the marginal unit of BMI
re relevant to a broad range of policy issues. These
ssues encompass estimates of the cost-effectiveness of
nterventions targeting adverse weight profiles, nationalal of Health Economics 70 (2020) 102300 17
health systems and by private insurers research priori-
ties, justifications for governmental interventions to target
adiposity-related externalities, and for the pricing of insur-
ance policies.
The results of our analysis may  be most relevant to pol-
icy changes that consider relatively modest changes in BMI,
since the amount of variance in BMI  explained by the SNPs
used is less than 2%, although our evidence that the effect of
BMI  on hospital costs is approximately linear would allow
some extrapolation of the effects of larger changes in BMI.
Any intervention targeting adiposity will appear rela-
tively more cost-effective if the marginal unit of adiposity
is higher, and evidence from our analysis suggests that this
is plausibly the case. Likewise, a relatively larger “prize”
for insurance companies and health systems of reducing
BMI  (where clinically appropriate to do so) has implica-
tions for the prioritization and funding of research (Claxton
and Sculpher, 2006; Jackson et al., 2019). Justifications
for government intervention, including policies such as
higher taxation on sugar-sweetened beverages, are gen-
erally motivated – at least in part – by the associated
external effects of health-comprising levels of adiposity
on various outcomes (Allcott et al., 2019; Cawley and
Meyerhoefer, 2012; Cawley et al., 2015b, 2019). Our causal
analysis demonstrates both that these effects exist in
relation to healthcare cost outcomes, and that they may
be larger than those estimated using conventional study
designs.
This overall relevance of our estimates depends on two
important conditions. The first is the idea of LATE as defined
and discussed above. As Basu (Basu, 2011) writes, “LATE is
an interpretable parameter when the observed variation in
the instrument defines the question for which the analyst
seeks an answer, e.g., if the analyst has access to an instru-
ment, Z, that takes two values (z and z′) and the question
he seeks to answer is precisely what happens when the
instrument is changed from z1 to z′.” This criterion is satis-
fied in the present case: the unit change in BMI  associated
with changes in the value of our BMI  instrument variable(s)
is precisely the type of policy question that we  wish to
answer. Thus, assuming LATE and the population of com-
pliers is an interesting population, we may  be content that
the LATE parameter is relevant to policy in this case. Indeed,
it is plausible that the effects of BMI  in compliers is likely to
be similar to the effects of BMI  on average across the pop-
ulation, so that LATE is identical to or close to the average
treatment effect,
The second issue is that of the stable unit treatment
value assumption (SUTVA). This encodes the assumption
that the outcome for an individual exposed to a treat-
ment (BMI in this case) is the same irrespective of the
mechanism used to assign the treatment (Rubin, 1986).
This ensures that the potential outcomes of the treatment
are well defined. The original motivation for using ran-
dom perturbations in genetic variation to identify causal
effects reflects this assumption (Davey Smith and Ebrahim,
2003): “The future potential of Mendelian randomization
will depend upon the elucidation of functional polymor-
phisms that mirror environmental exposures of interest.”
This reflects the concepts of phenocopy (an “environmen-
tal” effect that mirrors genetic variation) and genocopy
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(genetic variation that mirrors an environmental stimulus)
(Ebrahim and Davey Smith, 2008).
Our analysis fails to meet this assumption because we do
not know whether (hypothetically) increasing BMI  by one
unit through manipulating an individual’s diet, exercise
regime or environment is precisely identical to increasing
BMI  through a hypothetical manipulation of their geno-
type. This distinction can be seen by considering genetic
variants in the region of the FTO gene, an important effect
of which is to diminish satiety upon eating. As Burgess et al.
(2012) note, the consequence of modifying this gene will
be to affect food intake by an effect on satiety. This may  not
have an identical effect to an intervention that reduces BMI
by increasing exercise intensity or by an intervention such
as bariatric surgery.
The difference in timing of effect between, for exam-
ple, mid-life interventions targeting BMI  and genetically
elevated BMI  (determined at conception) is another exam-
ple of how Mendelian Randomization may  not satisfy the
stable unit treatment value assumption. Mendelian Ran-
domization estimates therefore do not measure the effect
of a randomized intervention on the population of inter-
est because our Mendelian Randomization models fail the
SUTVA in this case.
We  conclude that our preferred estimates (see above)
indicate that more conventional study designs underes-
timate the true causal impact of adiposity, but that the
precise magnitude of a genetically predicted change in
BMI  may  not accord with all other possible sources of
change in BMI, including those implemented by individual
or population-wide interventions. We  note that these types
of consideration may  apply in the same way to most if not
all other causal estimates (other than those obtained from
well-designed randomized controlled trials) of the associa-
tion between adiposity and healthcare costs, none of which
should be naively interpreted as the effect of randomizing
individuals in a population to higher or lower BMI.
Taking these considerations and qualifications into
account, we now offer a simple “back of the envelope” illus-
tration of the potential policy impact of our new estimates.
If we assume 50 million adults (roughly the size of the adult
population in the UK), then using the penalized weighted
median Mendelian Randomization estimate of the effect on
hospital costs of a marginal unit of BMI  (which is interme-
diate between the high IVW estimate and lower weighted
median estimate of £18.85) suggests costs due to one addi-
tional unit of BMI  as 50,000,000*1*£18.85 = £942,500,000.
Performing the same calculation but using instead the
multivariable conditional correlational estimate of £13.47
results in an estimate of additional costs of £673,500,000.
This amounts to a difference of £269,000,000 between the
estimates for a single year of one unit more of BMI  for all
adults. One of the many assumptions we make in this sim-
ple illustration is that effects obtained using the age profile
of adults in UK Biobank (most of whom were aged between
40 and 69 at the time of recruitment) also apply to younger
adults.This figure may  be interpreted as the additional costs
not available to the hospital system, in one year and
amongst all adults, under the higher rather than lower
estimates of a single marginal unit of BMI. A population-al of Health Economics 70 (2020) 102300
wide intervention to improve adult BMI  may  therefore
not be cost-effective under traditional estimates, but may
be cost-effective under the higher Mendelian Randomiza-
tion estimates. These types of consideration also apply to
decisions to prioritize research targeting BMI  compared to
other clinical areas.
6. Conclusion
We  have reported the first Mendelian Randomization
analysis to estimate the causal effect of adiposity on inpa-
tient hospital costs. Results suggest that conventional
adjusted multivariable analysis probably understates the
effect of BMI  on hospital costs. Findings from within-family
models were imprecise, and we  cannot discount the pos-
sibility of dynastic biases, although interpretation of these
models is complicated by limited power and the possibility
of a Type 1 error. Nevertheless, Mendelian Randomiza-
tion is a feasible and potentially valuable form of analysis
for health economics. The methods could be applied in
modelling economic outcomes for other traits, behaviours,
circumstances and diseases.
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